Tocotrienol
Information
- Drug Name
- Tocotrienol
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| Co-administration of isoprenoids (vitamin E isomer... | HMGCR | HMGCR UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04175470 | Active, not recruiting | Phase 2 | Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer | October 29, 2019 | December 2024 |
| NCT02705300 | Active, not recruiting | Phase 2 | Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer | May 6, 2016 | March 2025 |
| NCT01973400 | Completed | Phase 3 | Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus | June 2011 | December 2016 |
| NCT04496492 | Completed | Phase 2 | Preoperative Use of Tocotrienol From Annatto Bixa Orellana L. in Breast Cancer Patients: a Prospective Clinical Trial. | February 9, 2016 | July 6, 2017 |
| NCT01185769 | Completed | N/A | Study of Tocotrienol Absorption and Distribution Under Different Fat Status | September 2009 | September 2009 |
| NCT00889434 | Completed | N/A | Efficacy and Safety Study of EGCG/Tocotrienol in 18 Patients With Splicing-mutation-mediated Cystic Fibrosis (CF) | November 1, 2011 | April 16, 2015 |
| NCT04245865 | Recruiting | Phase 2 | Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer | June 26, 2020 | October 2024 |
| NCT02263924 | Unknown status | Phase 3 | Stroke and Tocotrienol: Unique Role in Neuroprotection | July 2015 | December 2018 |